Daiichi Sankyo initiates two new MorphoSys cancer programs
German antibody developer MorphoSys has initiated two cancer programs within its collaboration with Daiichi Sankyo. The Japanese drug major has selected two new target molecules against which MorphoSys will generate antibodies using its HuCAL technology.
Daiichi will carry out preclinical and clinical development and has worldwide marketing rights for all resulting products. MorphoSys receives exclusive license fees and stands to get milestones and royalties for the programs. Further financial details were not disclosed.
The two companies have been engaged in joint application of MorphoSys' phage display and antibody library since March 2006. In March 2008, Daiichi exercised its option to extend the contracting period until March 2011.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze